Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 2/3, TWO-PART STUDY TO EVALUATE THE EFFICACY AND LONG-TERM SAFETY WITH ORAL ETRASIMOD, 2 MG, ONCE DAILY IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS WITH A HISTORY OF PRIOR SYSTEMIC TREATMENT FAILURE

NCT05732454 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05732454
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05732454 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 2/3, TWO-PART STUDY TO EVALUATE THE EFFICACY AND LONG-TERM SAFETY WITH ORAL ETRASIMOD, 2 MG, ONCE DAILY IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS WITH A HISTORY OF PRIOR SYSTEMIC TREATMENT FAILURE
Lead sponsor
Pfizer
Phase
Phase 2/3
Overall status
Terminated
Start date
January 18, 2023
Completion date
April 29, 2024
Enrollment
58 (actual)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis, atopic dermatitis, unspecified, eczema, eczema, atopic